Redeye reiterates its valuation following the Q1 2024 report. We are encouraged by the all-time high net sales, although we recognise the challenges expected for growth in 2024 due to decreased municipal budgets in Sweden. Nevertheless, we maintain optimism regarding the newly launched Previct Drug, which has already gained significant attention in both Sweden and internationally.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/